Themes Uranium & Nuclear ETF (URAN) Quote

every stock has a harry on board 😇

Impressive EOD close, .005+ today.

please ignore this guy harry crumb, he is a old grumping person I think, always negative -

GM FOLKSSS

Caroline Kennedy is actively campaigning against her cousin’s appointment. I’m curious to see if RFK Jr gets approved or rejected by the Senate.

Last update 6 hrs ago
https://www.pacermonitor.com/public/case/51356241/PURDUE_PHARMA_LP_et_al_v_ELITE_LABORATORIES_INC,_et_al

anyone know how much short yesterday? where can I find these numbers? 😄

.82 + 46%

Last day of the Dragon.

one thing is true that Hi_Lo is saying that it takes a hugh time to put this company in line with the rules, already 2 years they took over 1780 !!!!

The recent discussion seems to prove that many espoused “trading shares” are misunderstood by their “owners” here.

Those of you ex-Industry are way ahead, but others when spinning a yarn should consider Tom Clancy’s research before raising his pen.

yikes...............thank goodness i left when i did

That would be very nice indeed.

Dumb&dumber Very good mentioned here, Tonix has a very high potential, with a lot of products in the pipeline!!!!

Peter Davis
@peter_brit
#dcvax $nwbo #gbm

As countries all over the world now roll out their plans for RWD and RWE the changes made by $nwbo to their trial design to incorporate contemporaneous, matched external control patients show their visionary leadership and insig

BS 2020 is a FUDSTER!

Here's another post where you're NOT SELLING until first partnership announcement.

Show me an aged post where you guide investors to trade the stock and we'll move on from all this fun (btw we have over a dozen posts that will embarrass).

X BOOOOOOM

https://x.com/nicosintichakis/status/1884562777232351434?s=61&t=KEFTLxsG2C318JcOnlHS4Q

For a micro-cap biotech with a $7M market cap, these positive trial developments are important for RNAZ's market position. The successful progression to Cohort 3 with favorable safety data reduces near-term clinical risk and potentially increases the probability of trial completion. The PK/PD data a

BE Studies Imminent.


ELTP

The Vyvanse generic market is still extremely underserved. Elite’s product is not stocked by Cardinal yet. I don’t know if McKesson or AmeriSource stock it yet. Elite is worth the current price of 46 cents without any Vyvanse sales, so I don’t mind holding. I will feel a lot more bullish when I

This stock don't sell weed products anymore the name will change in due time.

That’s not what he said.

He’s saying if they were put in receivership 16 years ago it would have been easier to have fixed the companies back then
But that boat has sailed

They fvcked up, too late for receivership now.

We are ending Conservatorship

IMO 3 is the lowest PPS!

Settlement 1- 5billion? Or Discovery 🤷🏻🤷🏻